
Following the launch of its oral weight loss pill Foundayo, Eli Lilly partners with telehealth companies like Amazon and Weight Watchers for distribution, with plans to expand to retail pharmacies. This move intensifies competition with Novo Nordisk's Wegovy, causing Novo Nordisk shares to decline.